Lundbeck ends development of idalopirdine for Alzheimer’s

Lundbeck has announced that it will not be furthering progress on its Alzheimer's disease drug idalopirdine following the publication of disappointing trial results.

Two phase III trials involving the treatment returned unsatisfactory results, despite it originally being intended to match Alzheimer's drugs produced by Lilly and Merck Sharp and Dohme and reduce the severity of some of the common symptoms associated with the degenerative condition.

Idalopirdine was originally approved by the US Food and Drug Administration to begin trials and was even fast-tracked through the process due to the promise it was believed to show.

However, Lundbeck revealed that the latest trials featuring idalopirdine failed to "demonstrate efficacy as observed in the positive clinical phase II study and hence do not suffice to support a regulatory submission".

Despite this setback, which had a subsequent knock-on effect on share prices, the pharmaceutical firm's chief executive officer Kare Schultz has said she is confident the company will perform well over the remainder of 2017, meeting the targets it has set itself.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: shironosov via iStock